Navigation Links
Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010

BIRMINGHAM, Ala., March 8 /PRNewswire/ -- Atherotech Inc. today announced it will be presenting research in two poster sessions and exhibiting its VAP® Cholesterol Test in booth #1311 at the American College of Cardiology (ACC) 59th Annual Scientific Session Exposition. The annual meeting takes place March 14-16, 2010, at the Georgia World Congress Center in Atlanta.  


The VAP (Vertical Auto Profile) Test, which identifies a far greater number of people at risk for heart disease than standard cholesterol tests, was utilized in Atherotech-sponsored research to be presented at the conference. This research is being presented at the Sub-classes of Lipoproteins session and the Epidemiology session in Hall B of the Georgia World Congress Center.

"The VAP Test continues to prove its value in the laboratory as an analytical research tool and in thousands of doctors' offices across the U.S. as a direct-measured, comprehensive lipid assessment," said Atherotech Chief Medical Officer Michael Cobble, M.D.

Poster presentation 1075-103 titled "Subfractions As Predictors of Angiographic Coronary Artery Disease Among Those With Normal and Abnormal LDL Levels" is being presented from 3:30-4:30 p.m. on Sunday, March 14. Poster presentation 1128-96 "Apolipoprotein AI Predicts Future Death and Myocardial Infarction in Patients Undergoing Coronary Angiography Even When They Have Normal Baseline HDL Levels" is being presented from 9:30-10:30 a.m. on Monday, March 15. Both presentations are moderated by Heidi T. May, Ph.D., M.S.P.H., an epidemiologist at the Intermountain Medical Center in Murray, Utah.

Information related to the above presentations is embargoed until the time of scientific presentation. Additional information will be presented at the scientific session.

Atherotech representatives will be available to discuss the VAP Cholesterol Test in booth #1311, and blood draws will be provided to qualified attendees during regular exhibit hours. Because LDL is directly measured, fasting is not required. Test results will be returned to individuals via mail after the ACC conference. However, results for individuals tested Sunday will be available at the Atherotech booth Tuesday prior to the end of the conference.

The VAP Test reports 22 separate components of cholesterol and is covered by Medicare and most private insurance carriers. Unlike other lipid profiles, the VAP Test includes Lp(a) at no additional cost, and reports all three lipoprotein parameters -- LDL, non-HDL and apoB -- considered necessary by the expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology. The VAP Test also identifies markers of metabolic syndrome, which is frequently associated with early diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB and the apoB/apoAI ratio.

Atherotech now provides physicians and cardiology practices with a single source for the VAP Cholesterol Test and more than a dozen cardiovascular and metabolic tests. Cardiometabolic testing available through Atherotech includes C-Reactive Protein (hsCRP), LpPLA2, ApoE genotype, NT-proBNP, Cystatin-C, T3 and T4 when TSH is abnormal, plus gamma-glutamyl transferase (GGT), a recognized cardiovascular risk biomarker.

The VAP Test is available nationwide. For more information call 877.901.8510 or visit

About Atherotech Inc.

Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit

SOURCE Atherotech Inc.

Back to top



SOURCE Atherotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... TEL AVIV, Israel , Nov. 24, 2015  Tikcro Technologies Ltd. ... be held on December 29, 2015 at 11:00 a.m. Israel ... & Co., Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... , election of Eric Paneth and Izhak Tamir ... and Rami Skaliter as external directors; , approval of an ...
Breaking Biology Technology:
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
(Date:10/27/2015)... YORK , Oct. 27, 2015 In ... major issues of concern for various industry verticals such ... is due to the growing demand for secure & ... in various ,sectors, such as hacking of bank accounts, ... for electronic equipment such as PC,s, laptops, and smartphones ...
Breaking Biology News(10 mins):